-- Earnings Flash (ATNX) ATHENEX Reports Q2 Revenue $31.5M
7:00AM ET 7/28/2022 MT Newswires...
Quotes Snapshot > ATNX
Athenex Inc ATNX:NASDAQ
Last Price$1.10Cboe Real-Time Last Sale as of 3:52PM ET 8/10/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change0.00(0.00%)
Bid (Size)$1.09 (1,000)
Ask (Size)$1.12 (400)
Day Low / High$1.06 - 1.15
Volume886.5 K
Read more news Recent News
Sector Update: Health Care Stocks Edging Lower at Close
4:02PM ET 7/11/2022 MT NewswiresHealth care stocks were narrowly lower this afternoon, with the NYSE Health Care Index sliding 0.2% while the SPDR Health Care Select Sector ETF (XLV) was...
Sector Update: Health Care Stocks Still Little Changed
1:31PM ET 7/11/2022 MT NewswiresHealth care stocks were narrowly mixed this afternoon, with the NYSE Health Care Index rising less than 0.1% while the SPDR Health Care Select Sector ETF...
Athenex to Sell China API Manufacturing Units to TiHe Capital for $19 Million
10:03AM ET 7/11/2022 MT NewswiresAthenex (ATNX) said Monday it has struck a deal to sell its China units, which are mainly engaged in the making of active pharmaceutical ingredients, to...
View all Commentary and Analysis
Athenex, Inc. (ATNX) CEO Johnson Lau on Q2 2022 Results - Earnings Call Transcript
8:06PM ET 7/28/2022 Seeking AlphaAthenex (ATNX) Investor Presentation - Slideshow
10:40AM ET 5/20/2022 Seeking AlphaAthenex, Inc.'s (ATNX) CEO Johnson Lau on Q1 2022 Results - Earnings Call Transcript
1:19PM ET 5/10/2022 Seeking AlphaAthenex, Inc. (ATNX) CEO Johnson Lau on Q4 2021 Results - Earnings Call Transcript
8:50PM ET 3/16/2022 Seeking AlphaCompany Profile
Business DescriptionAthenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY. View company web site for more details
| Address | Conventus Building Buffalo, New York 14203-1009 |
| Phone | +1.716.427.2950 |
| Number of Employees | 582 |
| Recent SEC Filing | 08/01/2022 4 |
| Chairman & Chief Executive Officer | Yiu Nam Lau |
| COO & President-Athenex Pharmaceutical Division | Jeff Yordon |
| Chief Financial Officer | Joe Annoni |
| Chief Scientific Officer | Michael Smolinski |
Company Highlights
| Price Open | $1.10 |
| Previous Close | $1.10 |
| 52 Week Range | $0.41 - 3.91 |
| Market Capitalization | $133.8 M |
| Shares Outstanding | 121.6 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/03/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.27 |
| Beta vs. S&P 500 | N/A |
| Revenue | $89.1 M |
| Net Profit Margin | -161.21% |
| Return on Equity | -302.04% |
Analyst Ratings as of 07/14/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |